President Trump And Drug Pricing: Rhetorical Improvement But Uncertainty Remains
In his first address to Congress, President Trump didn’t drop drug pricing as a theme, but he also didn’t accuse the industry of 'getting away with murder.' For innovators, that’s at least a rhetorical improvement. Now the debate becomes what the US president means by prices that are 'artificially' high.
You may also be interested in...
The disconnect between what Donald Trump says about drug pricing in unscripted settings and what the Administration says in more formal, policy-articulating contexts is very stark. For biopharma companies, the 'official' statements are reassuring – but it would be dangerous to discount Trump’s populist instincts altogether.
US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.